Cancer information / Cancer types / Bladder / Treatment / Immunotherapy

Alberta Health Services. (2013, October). Muscle Invasive and Locally Advanced/Metastatic Bladder Cancer Clinical Practice Guideline GU-002 (Version 5). Retrieved from:

American Cancer Society. (2016, January 26). Treating Bladder Cancer. Retrieved from:

American Society of Clinical Oncology. (2017, October). Bladder Cancer. Retrieved from:

Cancer Care Ontario. (2016, June). Drug Monograph: Pembrolizumab. Retrieved from:

Cancer Care Ontario. (2017). Bladder Cancer Diagnosis, Treatment and Follow-up Care Pathway Map (Version 2017.02). Retrieved from:

Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. (2016, October). Journal of Urology. 196(4):1021-1029. Retrieved from:

Drugs and Health Products, Health Canada. (2017, September 9). Regulatory Decision Summary: Keytruda. Retrieved from:

Drugs and Health Products, Health Canada. (2018, February 21). Summary Basis of Decision (SBD) for IMFINZI. Retrieved from:

Drugs and Health Products, Health Canada. (2018, May 31). Qualifying Notice: Bavencio. Retrieved from:

EMD Serono, a Division of EMD Inc, Canada. (2018, May). Product Monograph: Bavencio. Retrieved from:

Feldman AS, Efstathiou JA, Lee RJ, Dahl DM, Michaelson MD, Zietman AL. Cancer of the bladder, ureter, and renal pelvis. DeVita VT Jr, Lawrence TS, Rosenberg SA. (2015). Cancer: Principles and Practice of Oncology. (10th Edition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 65:896-916.

National Cancer Institute. (2018, April 12). Bladder Cancer Treatment (PDQ®) Health Professional Version. Retrieved from:

Penn Medicine. (2017, October 12). All About Bladder Cancer. University of Pennsylvania. Retrieved from: